F-star
F-star is an innovation-focused biotech company developing next-generation multispecific antibody therapeutics to transform the lives of patients with cancer and other serious diseases.
About
F-star is a biotech company dedicated to developing novel, next-generation multispecific antibody therapeutics, focusing on cancer and other serious diseases. Their proprietary, clinically validated antibody platform enables the creation of tetravalent (2+2) bispecific antibodies that bind multiple antigens, designed for potent and safe immune system activation. F-star leverages its Fcab® and mAb2® platforms for the rapid discovery and development of differentiated drugs, aiming to address patients with significant unmet medical needs. Their approach offers robust manufacturing, strong safety, and enhanced biological potency. F-star's mission is to deliver life-extending and quality-of-life-improving treatments, particularly for patients with advanced cancer who have limited options.
Products & Services
- Development of next-generation multispecific (tetravalent bispecific) antibody therapeutics
- Fcab® and mAb2® technology platforms for drug discovery
- Immunotherapies for cancer
- Clinical-stage drug candidates including FS118 (anti-LAG-3/PD-L1) and FS222 (CD137/PD-L1 tetravalent bispecific antibody)
- Preclinical and clinical drug candidate pipeline
- Scientific research collaborations and licensing of antibody technologies
Use Cases & Case Studies
- FS118 (anti-LAG-3/PD-L1 tetravalent bispecific antibody) investigated in clinical trials for advanced cancer and PD-L1 resistance
- FS222 (CD137/PD-L1 bispecific antibody) evaluated in clinical trials for immunotherapy in colorectal and other cancers
Partnerships & Collaborations
- Merck KGaA, Darmstadt, Germany
- Denali Therapeutics
- Janssen (Johnson & Johnson)
- Takeda
Awards & Recognition
-
Contact Information
Certifications & Compliance
- GDPR compliance (General Data Protection Regulation)